1. Home
  2. BIIB

as 03-28-2025 4:00pm EST

$
-
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.

Founded: 1978 Country:
United States
United States
Employees: N/A City: CAMBRIDGE
Market Cap: 20.5B IPO Year: 1991
Target Price: $220.50 AVG Volume (30 days): 1.7M
Analyst Decision: Buy Number of Analysts: 27
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: 11.18 EPS Growth: 40.28
52 Week Low/High: $128.51 - $238.00 Next Earning Date: 04-23-2025
Revenue: $9,675,900,000 Revenue Growth: -1.62%
Revenue Growth (this year): -3.06% Revenue Growth (next year): -0.49%

BIIB Daily Stock ML Predictions

Stock Insider Trading Activity of Biogen Inc. (BIIB)

Name Ticker Relationship Date Transaction AVG Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
SHERWIN STEPHEN A BIIB Director Mar 7 '25 Sell $150.02 8,760 $1,314,141.91 11,318

Share on Social Networks: